UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy

被引:7
|
作者
Diaz-Santa, Johana [1 ]
Rodriguez-Romanos, Rocio [1 ]
Osca, Gemma [1 ]
Pratcorona, Marta [2 ]
Garrido, Ana [2 ]
Coll, Rosa [1 ]
Moret, Carla [1 ]
Escoda, Lourdes [3 ]
Tormo, Mar [4 ]
Heras, Inma [5 ]
Arnan, Montse [6 ]
Vives, Susanna [7 ]
Salamero, Olga [8 ]
Lloveras, Natalia [1 ]
Bargay, Joan [9 ]
Sampol, Antonia [10 ]
Cruz, David [1 ]
Garcia, Antoni [11 ]
Quinones, Teresa [1 ]
Esteve, Jordi [12 ]
Sierra, Jorge [2 ]
Gallardo, David [1 ]
机构
[1] Univ Girona, Hematol Dept, Catalan Inst Oncol ICO, Inst Invest Biomed Girona IDIBGI, Girona, Spain
[2] Univ Autonoma Barcelona, Hosp Santa Creu i St Pau, Inst Invest Biomed St Pau, Hematol Dept, Barcelona, Spain
[3] Hosp Joan 23, Hematol Dept, Catalan Inst Oncol ICO, Tarragona, Spain
[4] Hosp Clin, Hematol Dept, Valencia, Spain
[5] Univ Hosp Morales Meseguer, Dept Hematol, Murcia, Spain
[6] Catalan Inst Oncol ICO, Dept Hematol, Barcelona, Spain
[7] Josep Carreras Leukemia Res Inst IJC, Hematol Dept, Catalan Inst Oncol ICO, Barcelona, Spain
[8] Hosp Vall dHebro, Hematol Dept, Barcelona, Spain
[9] Hosp Son Llatzer, Hematol Dept, Palma De Mallorca, Spain
[10] Hosp Son Espases, Hematol Dept, Palma De Mallorca, Spain
[11] Hosp Arnau Vilanova, Hematol Dept, Lleida, Spain
[12] Univ Barcelona, Hematol Dept, Inst Invest Biomed August Pi i Sunyer IDIBAP, Hosp Clin, Barcelona, Spain
关键词
ACUTE MYELOGENOUS LEUKEMIA; POLYMORPHISMS; MUTATIONS; CANCER; ADULTS; IMPACT; GENE; 1A1;
D O I
10.1038/s41375-020-0784-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The treatment of acute myeloid leukemia (AML) is adjusted according to cytogenetic risk factors and molecular markers. Cytarabine remains the main drug to treat AML, and several studies have explored the prognostic relevance of the genotype of cytarabine metabolizing enzymes in AML. Glucuronidation has been identified to be relevant in the cytarabine clearance, but there are still few data concerning the clinical impact of genetic polymorphisms known to condition the activity of UDP-glucuronosyl transferases in AML patients. Here we report the association between the UGT1A1 rs8175347 genotype and the clinical outcome of 455 intermediate-risk cytogenetic AML patients receiving cytarabine-based chemotherapy. Patients with the UGT1A1*28 homozygous variant (associated to a lower UGT1A1 activity) had a lower overall survival (OS) (25.8% vs. 45.5%;p: 0.004). Multivariate analysis confirmed this association (p: 0.008; HR: 1.79; 95% CI: 1.16-2.76). Subgroup analysis showed the negative effect of the UGT1A1*28 homozygous genotype on OS in women (14.8% vs. 52.7%;p: 0.001) but not in men. This lower OS was associated with longer neutropenia after consolidation chemotherapy and with higher mortality without previous relapse, suggesting an association between a low glucuronidation activity and mortal toxic events.
引用
收藏
页码:2925 / 2933
页数:9
相关论文
共 50 条
  • [21] Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy
    Song, Ju Han
    Cho, Kyung-Min
    Kim, Hyeoung-Joon
    Kim, Yeo-Kyeoung
    Kim, Nan Young
    Kim, Hee-Je
    Lee, Tae-Hyang
    Hwang, Seung Yong
    Kim, Tae Sung
    ONCOLOGY REPORTS, 2015, 34 (01) : 488 - 494
  • [22] Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older patients with acute myelogenous leukemia
    Schiller, G
    Lee, M
    LEUKEMIA & LYMPHOMA, 1997, 25 (1-2) : 111 - 119
  • [23] Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia A Randomized Clinical Trial
    Bornhaeuser, Martin
    Schliemann, Christoph
    Schetelig, Johannes
    Roellig, Christoph
    Kramer, Michael
    Glass, Bertram
    Platzbecker, Uwe
    Burchert, Andreas
    Haenel, Mathias
    Mueller, Lutz P.
    Klein, Stefan
    Bug, Gesine
    Beelen, Dietrich
    Roesler, Wolf
    Schaefer-Eckart, Kerstin
    Schmid, Christoph
    Jost, Edgar
    Lenz, Georg
    Tischer, Johanna
    Spiekermann, Karsten
    Pfirrmann, Markus
    Serve, Hubert
    Stoelzel, Friedrich
    Alakel, Nael
    Middeke, Jan Moritz
    Thiede, Christian
    Ehninger, Gerhard
    Berdel, Wolfgang E.
    Stelljes, Matthias
    JAMA ONCOLOGY, 2023, 9 (04) : 519 - 526
  • [24] The Impact of Allogeneic Hematopoietic Stem-Cell Transplantation on Outcome of the Patients with Intermediate-Risk Acute Myeloid Leukemia
    Wang, Ying
    Wei, Hui
    Lin, Dong
    Zhou, Chunlin
    Liu, Bingcheng
    Qiu, Shaowei
    Gong, Benfa
    Zhang, Guangji
    Liu, Kaiqi
    Wei, Shuning
    Liu, Yuntao
    Gong, Xiaoyuan
    Zhao, Xingli
    Li, Yan
    Gu, Runxia
    Mi, Yingchang
    Wang, Jianxiang
    BLOOD, 2016, 128 (22)
  • [25] IS GENOTYPING OF UGT1A1 REALLY USEFUL FOR GYNECOLOGIC CANCER PATIENTS TREATED WITH IRINOTECAN-BASED CHEMOTHERAPY?
    Takano, M.
    Yoshikawa, T.
    Morikazu, M.
    Tadashi, A.
    Hiroaki, S.
    Kento, K.
    Hiroki, I.
    Hideki, I.
    Masaya, N.
    Takahiro, S.
    Takahiro, N.
    Hiroko, M.
    Tomoko, G.
    Hidenori, S.
    Yoshihiro, K.
    Kenichi, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 425 - 425
  • [26] IS GENOTYPING OF UGT1A1 REALLY USEFUL FOR GYNECOLOGIC CANCER PATIENTS TREATED WITH IRINOTECAN-BASED CHEMOTHERAPY?
    Takano, M.
    Yoshikawa, T.
    Morikazu, M.
    Tadashi, A.
    Hiroaki, S.
    Kento, K.
    Hiroki, I.
    Hideki, I.
    Masaya, N.
    Takahiro, S.
    Takahiro, N.
    Hiroko, M.
    Tomoko, G.
    Hidenori, S.
    Yoshihiro, K.
    Kenichi, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1002 - 1002
  • [27] IS GENOTYPING OF UGT1A1 REALLY NEEDED FOR GYNECOLOGIC CANCER PATIENTS TREATED WITH IRINOTECAN-BASED CHEMOTHERAPY?
    Takano, M.
    Goto, T.
    Miyamoto, M.
    Kato, M.
    Sasaki, N.
    Aoyama, T.
    Soyama, H.
    Shibutani, T.
    Matsuura, H.
    Hirata, J.
    Sasa, H.
    Furuya, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1294 - 1294
  • [28] Molecular markers predicting clinical outcome in patients with intermediate-risk acute myeloid leukemia receiving autologous stem cell transplantation.
    Esteve, Jordi
    Kalko, Susana
    Torrebadell, Montserrat
    Camos, Mireia
    Jares, Pedro
    Rozman, Maria
    Pratcorona, Marta
    Brunet, Salut
    Nomdedeu, Josep
    Carrio, Ana
    Costa, Dolors
    Montserrat, Emili
    BLOOD, 2007, 110 (11) : 186A - 186A
  • [29] Outcome and toxicities associated to chemotherapy in children with acute lymphoblastic leukemia and Gilbert syndrome. Usefulness of UGT1A1 mutational screening
    Berrueco, R.
    Alonso-Saladrigues, A.
    Martorell-Sampol, L.
    Catala-Temprano, A.
    Ruiz-Llobet, A.
    Toll, T.
    Torrebadell, M.
    Naudo, M.
    Camos, M.
    Rives, S.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (07) : 1195 - 1201
  • [30] High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia
    Oya, Shuki
    Ozawa, Hidetoshi
    Morishige, Satoshi
    Maehiro, Yoshimi
    Umeda, Masahiro
    Takaki, Yusuke
    Fukuyama, Toshinobu
    Yamasaki, Yoshitaka
    Nakamura, Takayuki
    Yamaguchi, Maki
    Aoyama, Kazutoshi
    Mouri, Fumihiko
    Nagafuji, Koji
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (03) : 297 - 304